Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 489 - #Psychedelic Spotlight-(CSE: $SPOR.C) (OTC: $TRMNF) (NEO: MMED) (OTCQB: $MMEDF)
Today's podcast sponsored by Cannabis Suisse Corp. (OTC: $CSUI), a fully licensed cannabis cultivation and distribution company in Switzerland
Delta, Kelowna, BC, October 30, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/103020-StocksToWatch.mp3
Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/10301SPOR-TRMNF-NMED-MMEDF.asp
Hear the investor ideas potcast on Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
Today’s podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's facilities for producing cannabis are based in Dietikon, Switzerland, and contain the art surveillance equipment to enable an around the clock webcast. Cannabis Suisse grows high quality, organic cannabis with sustainable, all-natural principles. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse proprietary trademarked MoldStandard is a quantitative microbiology method for analyzing yeast and mold counts in harvested cannabis plants. Cannabis Suisse proprietary trademarked CannaMec is a method for quantifying and removing residual solvents during packaging and storage of CBD products. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.
In today’s podcast we look at a few public and private company announcements focussing specifically on the emerging psychedelic sector.
NEW WAVE HOLDINGS CORP. (CSE: SPOR) (OTC:TRMNF) an investment issuer that provides capital and support services, announced it will bring Microdose to Vancouver November 1st - 10th to start production for the next phase of "The World on Drugs" documentary.
The team at New Wave is pleased to announce that Microdose is traveling to Vancouver from November 1-10th, to film the next phase of the upcoming documentary "The World on Drugs". The production aims to illuminate a bold commentary on drug policy, psychedelic medicine and mental health comes at a pivotal moment in our collective evolution. The sharp increase in opioid-related overdose deaths in B.C. highlight the urgent need for new treatments and policy, providing the unique opportunity to spotlight psychedelic medicine. We have scheduled interviews with leading experts in their respective fields, and would love to hear your suggestions for interview candidates, key locations, or critical subject matter that should be filmed in Vancouver, please fill out this open feedback/application form.
"We would like to thank New Wave Holdings for being our inaugural sponsor for this next phase of our international effort to document the intersection of mental health, psychedelic medicine and global drug policy around the world. We are committed to building a compelling, objective narrative by listening to the experts, this documentary will truly be a team effort." Microdose CEO - Patrick Moher
Pilot footage for "The World on Drugs" was captured in Mexico where the Microdose team met with notable thought leaders, clinicians and psychedelic medicine providers. For any general partnership inquiries, please reach out to Connor Haslem at: Connor@microdose.buzz.
"The Microdose team hopes to continue the journey by heading to Portugal, where full drug decriminalization provides fascinating insight into a potential, more progressive way forward. We also intend on going to Jamaica, another iconic location significantly impacted by the War on Drugs that is pioneering new mental health treatments. As our worldwide documentary filmmaking journey progresses, we hope to illuminate the potential of psychedelic medicine to disrupt the mental health crisis across the globe." - Patrick Moher continued.
The data form: If you or anyone you know wants to contribute or is interested to collaborate on this project, please fill out this form. We do have a limited filming period that is available, so unfortunately we won't be able to connect directly with all submissions-but, everybody that fills this form out on behalf of somebody or behalf of themselves will get a free copy of the completed film as a thank you gift for your contribution.
If you are interested in getting involved with this dynamic documentary filmmaking project in terms of collaboration, sponsorship or general input, please reach out to Connor Haslem at: Connor@microdose.buzz
MagicMed Industries Inc. announced that it has entered into a Research Contract and a Facilities Use Agreement with the University of Calgary. The Agreements provide MagicMed with further scientific and laboratory support to accelerate development of its psychedelic derivatives patent library, the PsybraryTM.
"The University of Calgary is excited to partner with MagicMed, an innovative company pursuing psychedelics research," says Associate Vice-President (Research – Innovation), Dr. Steve Larter. "Partnerships like this combine frontline discovery with providing real solutions to society and create opportunities for our researchers and students to help bring cutting-edge knowledge to market."
"The additional resources that the University of Calgary is providing to MagicMed compliment and enhance our strengths," says Dr. Joseph Tucker, CEO MagicMed. "This collaboration places MagicMed in a position to expand the breadth and depth of the psychedelic derivatives contained in the MagicMed PsybraryTM."
Through the Agreements, MagicMed will be able to leverage new state of the art equipment and laboratory space at the University of Calgary, as well as draw upon its world-class expertise. Laboratory and resource costs of the MagicMed PsybraryTM expansion will be efficiently allocated while development progress will be expedited.
Mind Medicine Inc. (NEO: MMED) (OTCQB: MMEDF) announced that it has closed its previously announced bought deal short form prospectus offering, including the exercise in full of the underwriter's over-allotment option. In connection with the Offering, the Company issued 27,381,500 units of the Company at a price per Unit of $1.05 for gross proceeds of $28,750,575. Canaccord Genuity Corp. acted as sole bookrunner and underwriter in the Offering.
Each Unit comprises one subordinate voting share of the Company and one-half of one Subordinate Voting Share purchase warrant. Each Warrant entitles the holder thereof to purchase one Subordinate Voting Share at an exercise price of $1.40 until October 30, 2023. The Warrants will be listed for trading on the facilities of the NEO Exchange Inc. under the symbol "MMED.WS", subject to the final approval of the NEO.
MindMed Co-Founder & Co-CEO, J.R. Rahn said "The strong institutional investor interest for this oversubscribed financing demonstrates the vast appetite for companies pursuing clinical trials of psychedelic medicines with the FDA and other regulatory bodies. With our sights set on a NASDAQ up-listing, this fresh funding will further assist the MindMed team in our mission to build the most diverse development pipeline of psychedelic inspired medicines and experiential therapies for patients."
Post-financing the Company now has cash reserves of CAD $50.1m (USD $37.8m) to enable continued progress of its clinical trial pipeline of psychedelic inspired medicines and experiential therapies.
The Company intends to use the net proceeds of the Offering for investment in its research and clinical development initiatives, including its 18-MC addiction treatment program derived from the psychedelic ibogaine, lysergic acid diethylamide (LSD) microdose program for Adult ADHD, Project Lucy focused on LSD experiential therapy for anxiety disorders, University Hospital Basel Liechti Lab research and development collaboration, its partnership with NYU Langone Health for a Psychedelic Medicine Research Training Program, and for general working capital and corporate development purposes.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.
MindMed is a psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and experiential therapies to address addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed team brings extensive biopharmaceutical experience to the Company's groundbreaking approach to developing the next generation of psychedelic inspired medicines and experiential therapies.
In closing today’s podcast if you are still on the fence about the benefits of psychedelic medicine (or cannabis) we’ve included two book recommendations that do an amazing job of illustrating the importance and necessity of whole plant based medicines in the modern world, especially in a COVID world.
The first is “Psychedelic Medicine: The Healing Powers of LSD, MDMA, Psilocybin, and Ayahuasca” which explores the potential of psychedelics as medicine and the intersections of politics, science, and psychedelics as well as offers non-technical summaries of the most recent, double-blind, placebo-controlled studies with MDMA, psilocybin, LSD, and ayahuasca. This book includes the work of Rick Doblin, Stanislav Grof, James Fadiman, Julie Holland, Dennis McKenna, David Nichols, Charles Grob, Phil Wolfson, Michael and Annie Mithoefer, Roland Griffiths, Katherine MacLean, and Robert Whitaker and is available on Amazon or if you’re in Canada, you can buy online from my local head shop Mary Jane’s HQ.
The second has garnered more controversy but is, in my opinion, a must read during this time in history particularly, is “Thus Spoke the Plant: A Remarkable Journey of Groundbreaking Scientific Discoveries and Personal Encounters with Plants” by Monica Gagliano. This book is both haunting and profound and offers a new perspective on plants, medicine and communication with nature in the modern world. This book is also available on Amazon and you listen to her in depth discussion on plant consciousness on Youtube to hear her words directly.
Once again, today’s podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: Cannabis Suisse Corp. (OTC: CSUI),is a paid featured company on Investorideas.com More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about
publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
No comments:
Post a Comment